Medical Marijuana Use in HIV+ Patients: Probability Survey (MMS)

This study has been completed.

Sponsor:

Collaborator:

National Institute on Drug Abuse (NIDA)

Information provided by (Responsible Party):

Mark Greenwald, PhD, Wayne State University

ClinicalTrials.gov Identifier:

NCT01536912

First received: February 16, 2012

Last updated: July 29, 2015

Last verified: July 2015

History of Changes

Purpose

More scientific information is needed about medical marijuana use among HIV positive patients. There is conflicting information about the use of marijuana, use of medical marijuana, and the associations between them and health status/health risk behaviors/health care utilization. In addition, it is not clear whether patients who participate in prospective clinical studies differ from participants who do not participate; if there are differences between those two groups, then this would limit generalizability of knowledge about these issues.

The goal of this project is to describe the use of marijuana among HIV positive patients and its association with health status/health risk behaviors/health care utilization.

Condition
HIV Positive


Study Type:	Observational
Study Design:	Observational Model: Case-Only
Official Title:	Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients: Probability Survey

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Marijuana

U.S. FDA Resources

Further study details as provided by Wayne State University:


Enrollment:	218
Study Start Date:	February 2012
Study Completion Date:	December 2014
Primary Completion Date:	December 2014 (Final data collection date for primary outcome measure)

Detailed Description:

Participants will answer questions about marijuana, medical marijuana, and other drug use. We will also ask about health and steps participants take to keep healthy. The study will take up to one hour to complete.

Participants will also be asked to sign a release of information form. This form would allow us to look at medical records at the HIV clinic.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV positive

Criteria

Inclusion Criteria:

Patients in the HIV clinic
HIV positive

Exclusion Criteria:

Lack of english

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01536912

Locations


United States, Michigan
Wayne State University (HIV clinic, Tolan Park Medical Building)
Detroit, Michigan, United States, 48201

Sponsors and Collaborators

Wayne State University

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Mark Greenwald, PhD	Wayne State University

More Information


Responsible Party:	Mark Greenwald, PhD, Professor, Wayne State University
ClinicalTrials.gov Identifier:	NCT01536912 History of Changes
Other Study ID Numbers:	MMS-1 R01DA032678
Study First Received:	February 16, 2012
Last Updated:	July 29, 2015
Health Authority:	United States: Federal Government United States: Institutional Review Board

Keywords provided by Wayne State University:


HIV positive

Additional relevant MeSH terms:


HIV Seropositivity HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections	Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

ClinicalTrials.gov processed this record on September 30, 2016

To Top